Novartis Gene Therapies (formerly known as AveXis) is a biotech company developing innovative treatments for rare and life-threatening genetic diseases. It offers AVXS-101, a gene therapy product candidate for the treatment of spinal muscular atrophy Type 1. The company partners with academics, biotechnology, pharmaceutical companies, and healthcare investors.